title: Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer.
abstract: BACKGROUND
  The aim of this study was to determine the activity and safety of pegylated liposomal doxorubicin (PLD; Caelyx) and docetaxel combination as first-line treatment in patients with metastatic breast cancer (MBC).
  
  
  METHODS
  Forty-four patients with a median age of 63 years were treated with PLD 30 mg/m(2) (day 1) and docetaxel 75 mg/m(2) (day 2) every 3 weeks for six cycles. Recombinant human Granulocyte Colony-Stimulating Factor (rhG-CSF) could be used in patients with grade > or =3 neutropenia after the first cycle.
  
  
  RESULTS
  Forty-two of 44 patients were assessable for response. The response rate (RR) was 64.3% (95% confidence interval 49.8% to 78.8%). Six patients (14.3%) achieved complete response (complete disappearance of all measurable and assessable disease lasting at least 4 weeks, no new lesions, no disease-related symptoms), partial response was observed in 21 patients (50%) > or =50% decrease of measureable disease lasting at least 4 weeks, no progression of assessable disease, no new lesions, no disease-related symptoms), eight patients had stable disease and seven patients progressive disease. Median disease-free and overall survival were not reached, but were in excess of 17 months (range 6-17 months). Twenty of the patients had received previous adjuvant chemotherapy (10 with epirubicin-containing regimen with a median cumulative dose of 400 mg/m(2)). Grade > or =3 neutropenia occurred in 18.4% and neutropenic fever in 9% of patients. Palmar-plantar erythrodysesthesia was observed in four patients. Dose reduction was necessary in seven patients. Two patients discontinued treatment: one due to prolonged grade 3-4 neutropenia and one due to neurotoxicity. No treatment-related deaths occurred.
  
  
  CONCLUSIONS
  The combination of PLD and docetaxel achieved high RRs with acceptable toxicity as first-line treatment in MBC.
authors.affiliation: First Department of Medical Oncology, St Savvas Anticancer-Oncologic Hospital, Athens, Greece. karam@otenet.gr
authors.forename: A
authors.initials: A
authors.lastname: Alexopoulos
authors.forename: M V
authors.initials: MV
authors.lastname: Karamouzis
authors.forename: H
authors.initials: H
authors.lastname: Stavrinides
authors.forename: A
authors.initials: A
authors.lastname: Ardavanis
authors.forename: K
authors.initials: K
authors.lastname: Kandilis
authors.forename: J
authors.initials: J
authors.lastname: Stavrakakis
authors.forename: C
authors.initials: C
authors.lastname: Georganta
authors.forename: G
authors.initials: G
authors.lastname: Rigatos
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008081:Liposomes; D008875:Middle Aged; D009362:Neoplasm Metastasis; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D008081:Liposomes; D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin